Investment Thesis
Tvardi Therapeutics exhibits severe operational deterioration with a 66% YoY revenue collapse and unsustainable operating losses of -274.5%, indicating failed commercialization or partnership loss. Despite maintaining adequate liquidity (19.9M cash with 2.9 years of runway at current burn), the company faces existential risk without significant pipeline catalysts or capital restructuring, compounded by the inherent biotech execution risk and lack of management insider activity.
Strengths
- Zero debt with 0.00x debt-to-equity ratio eliminates solvency risk in near term
- Cash represents 77% of total assets providing 2.9 years of operating runway at current burn rate
- Current and quick ratios above 2.0x indicate adequate liquidity for obligations
Risks
- Catastrophic 66% YoY revenue decline suggesting failed product commercialization or major partnership termination
- Unsustainable negative free cash flow of -6.9M annually with operating margin of -274.5% and no path to profitability visible
- Minimal revenue base (2.6M) with pharmaceutical sector risk indicates no commercially viable products
- Potential dilution imminent as cash runway of 2.9 years insufficient for typical biotech development timelines
- Zero insider Form 4 filings in 90 days signals low management confidence in company direction
Key Metrics to Watch
- Quarterly revenue stabilization or further decline trajectory
- Monthly cash burn rate and updated remaining runway calculations
- Clinical pipeline progress announcements and partnership or licensing developments
- Operating cash flow trend toward positive territory indicating operational improvements
- Gross margin expansion when revenue stabilizes indicating potential path to unit economics viability
Financial Metrics
Revenue
2.6M
Net Income
-6.8M
EPS (Diluted)
$-0.73
Free Cash Flow
-6.9M
Total Assets
25.8M
Cash
19.9M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-274.5%
Net Margin
-264.9%
ROE
-46.9%
ROA
-26.4%
FCF Margin
-268.8%
Balance Sheet & Liquidity
Current Ratio
2.25x
Quick Ratio
2.17x
Debt/Equity
0.00x
Debt/Assets
43.8%
Interest Coverage
-12.64x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-14T09:23:17.888536 |
Data as of: 2026-03-31 |
Powered by Claude AI